

Author's Accepted Manuscript

Antibody Therapy Alone and in Combination with Targeted Drugs in Chronic Lymphocytic Leukemia

Tadeusz Robak, Jerzy Z. Blonski, Pawel Robak



PII: S0093-7754(16)00016-6
DOI: <http://dx.doi.org/10.1053/j.seminoncol.2016.02.010>
Reference: YSONC51914

To appear in: *Semin Oncol*

Cite this article as: Tadeusz Robak, Jerzy Z. Blonski, Pawel Robak, Antibody Therapy Alone and in Combination with Targeted Drugs in Chronic Lymphocytic Leukemia, *Semin Oncol*, <http://dx.doi.org/10.1053/j.seminoncol.2016.02.010>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Antibody Therapy Alone and in Combination with Targeted Drugs in Chronic Lymphocytic Leukemia

Tadeusz Robak¹, Jerzy Z Blonski¹, Pawel Robak²

Departments of Hematology¹ and Experimental Hematology², Medical University of Lodz, Lodz, Poland

Short title: Monoclonal Antibodies for CLL

Corresponding author: Prof. Tadeusz Robak,

Department of Hematology

Medical University of Lodz

93-510 Lodz

Ciołkowskiego 2

Poland

Email: robaktad@csk.umed.lodz.pl

ABSTRACT

The development of nonchemotherapeutic agents, including monoclonal antibodies (mAbs) and other targeted drugs, makes chemotherapy-free treatment an attractive option for chronic lymphocytic leukemia (CLL). The classical mAb, rituximab, has been authorised for use in both first-line and second-line therapy for CLL. New mAbs directed against CD20, ofatumumab and obinutuzumab (GA-101), have also been approved for the treatment of this disease. Recently, several new mAbs with potential benefits over the approved anti-CD20 antibodies have been developed for use in CLL. Anti-CD37, anti-CD19 and anti-CD40 mAbs

Download English Version:

<https://daneshyari.com/en/article/2161753>

Download Persian Version:

<https://daneshyari.com/article/2161753>

[Daneshyari.com](https://daneshyari.com)